

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

## Quantitative Structure–Cytotoxicity Relationship of Azulene Amide Derivatives

KANA IMANARI<sup>1</sup>, MASASHI HASHIMOTO<sup>1</sup>, HIDETSUGU WAKABAYASHI<sup>1</sup>,  
NORIYUKI OKUDAIRA<sup>2</sup>, KENJIRO BANDOW<sup>3</sup>, JUNKO NAGAI<sup>4</sup>, MINEKO TOMOMURA<sup>3</sup>,  
AKITO TOMOMURA<sup>3</sup>, YOSHIHIRO UESAWA<sup>4</sup> and HIROSHI SAKAGAMI<sup>5</sup>

<sup>1</sup>*Faculty of Science, Josai University, Sakado, Japan;*

*Division of <sup>2</sup>Pharmacology and <sup>3</sup>Biochemistry, and <sup>5</sup>Meikai University Research Institute of Odontology (M-RIO),  
Meikai University School of Dentistry, Sakado, Japan;*

<sup>4</sup>*Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan*

*Reprinted from*

ANTICANCER RESEARCH 39: 3507-3518 (2019)

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005  
ISSN (online): 1791-7530

## Editorial Board

- P. A. ABRAHAMSSON, Malmö, Sweden  
B. B. AGGARWAL, Houston, TX, USA  
T. AKIMOTO, Kashiwa, Chiba, Japan  
P. Z. ANASTASIADIS, Jacksonville, FL, USA  
A. ARGIRIS, San Antonio, TX, USA  
J. P. ARMAND, Toulouse, France  
V. I. AVRAMIS, Los Angeles, CA, USA  
D.-T. BAU, Taichung, Taiwan, ROC  
G. BAUER, Freiburg, Germany  
E. E. BAULIEU, Le Kremlin-Bicetre, France  
E. J. BENZ, Jr., Boston, MA, USA  
J. BERGH, Stockholm, Sweden  
F. T. BOSMAN, Lausanne, Switzerland  
M. BOUVET, La Jolla, CA, USA  
J. BOYD, Miami, FL, USA  
G. BROICH, Monza, Italy  
Ø. S. BRULAND, Oslo, Norway  
J. M. BUATTI, Iowa City, IA, USA  
M. M. BURGER, Basel, Switzerland  
M. CARBONE, Honolulu, HI, USA  
C. CARLBERG, Kuopio, Finland  
J. CARLSSON, Uppsala, Sweden  
A. F. CHAMBERS, London, ON, Canada  
P. CHANDRA, Frankfurt am Main, Germany  
L. CHENG, Indianapolis, IN, USA  
J.-G. CHUNG, Taichung, Taiwan, ROC  
R. CLARKE, Washington, DC, USA  
E. DE CLERCQ, Leuven, Belgium  
W. DEN OTTER, Amsterdam, The Netherlands  
E. P. DIAMANDIS, Toronto, ON, Canada  
G. TH. DIAMANDOPOULOS, Boston, MA, USA  
L. EGEVAD, Stockholm, Sweden  
D. W. FELSHER, Stanford, CA, USA  
J. A. FERNANDEZ-POL, Chesterfield, MO, USA  
I. J. FIDLER, Houston, TX, USA  
A. P. FIELDS, Jacksonville, FL, USA  
H. FU, Atlanta, GA, USA  
B. FUCHS, Zurich, Switzerland  
D. FUCHS, Innsbruck, Austria  
D. FUKUMURA, Boston, MA, USA  
G. GABBIANI, Geneva, Switzerland  
R. GANAPATHI, Charlotte, NC, USA  
A. F. GAZDAR, Dallas, TX, USA  
A. GIORDANO, Philadelphia, PA, USA  
G. GITSCH, Freiburg, Germany  
M. GNANT, Vienna, Austria  
R. H. GOLDFARB, Guilford, CT, USA  
A. HELLAND, Oslo, Norway  
L. HELSON, Quakertown, PA, USA  
R. HENRIKSSON, Umeå, Sweden  
R. M. HOFFMAN, San Diego, CA, USA  
S. C. JHANWAR, New York, NY, USA  
J. V. JOHANNESSEN, Oslo, Norway  
R. JONES, London, UK  
B. KAINA, Mainz, Germany  
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland  
D. G. KIEBACK, Schleswig, Germany  
R. KLAPDOR, Hamburg, Germany  
H. KOBAYASHI, Bethesda, MD, USA  
S. D. KOTTARIDIS, Athens, Greece  
G. R. F. KRUEGER, Köln, Germany  
Pat M. KUMAR, Manchester, UK  
Shant KUMAR, Manchester, UK  
O. D. LAERUM, Bergen, Norway  
F. J. LEJEUNE, Lausanne, Switzerland  
S. LINDER, Linköping, Sweden  
L. F. LIU, Piscataway, NJ, USA  
D. M. LOPEZ, Miami, FL, USA  
E. LUNDGREN, Umeå, Sweden  
Y. MAEHARA, Fukuoka, Japan  
J. MAHER, London, UK  
J. MARESCAUX, Strasbourg, France  
J. MARK, Skövde, Sweden  
S. S. MARTIN, Baltimore, MD, USA  
S. MITRA, Houston, TX, USA  
S. MIYAMOTO, Fukuoka, Japan  
S. MONCADA, Manchester, UK  
M. MUELLER, Villingen-Schwenningen, Germany  
F. M. MUGGIA, New York, NY, USA  
M. NAMIKI, Kanazawa, Ishikawa, Japan  
R. NARAYANAN, Boca Raton, FL, USA  
K. NILSSON, Uppsala, Sweden  
S. PATHAK, Houston, TX, USA  
J.L. PERSSON, Malmö, Sweden  
G. J. PILKINGTON, Portsmouth, UK  
C. D. PLATSOUKAS, Norfolk, VA, USA  
A. POLLIACK, Jerusalem, Israel  
D. RADES, Lübeck, Germany  
M. RIGAUD, Limoges, France  
U. RINGBORG, Stockholm, Sweden  
M. ROSELLI, Rome, Italy  
S.T. ROSEN, Duarte, CA, USA  
A. SCHAUER, Göttingen, Germany  
M. SCHNEIDER, Wuppertal, Germany  
J. SEHOULI, Berlin, Germany  
A. SETH, Toronto, ON, Canada  
G. V. SHERBET, Newcastle-upon-Tyne, UK  
A. SLOMINSKI, Birmingham, AL, USA  
G.-I. SOMA, Kagawa, Japan  
G. S. STEIN, Burlington, VT, USA  
T. STIGBRAND, Umeå, Sweden  
T. M. THEOPHANIDES, Athens, Greece  
P. M. UELAND, Bergen, Norway  
H. VAN VLIERBERGHE, Ghent, Belgium  
R. G. VILE, Rochester, MN, USA  
M. WELLER, Zurich, Switzerland  
J. WESTERMARCK, Turku, Finland  
B. WESTERMARK, Uppsala, Sweden  
Y. YEN, Taipei, Taiwan, ROC  
M.R.I. YOUNG, Charleston, SC, USA  
B. ZUMOFF, New York, NY, USA  
G. J. DELINASIOS, Athens, Greece  
Managing Editor and  
Executive Publisher  
J. G. DELINASIOS, Athens, Greece  
Managing Editor (1981-2016)

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org  
Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IAR is a member of UICC. For more information about ANTICANCER RESEARCH, IAR and the Conferences, please visit the IAR website: www.iia-anticancer.org

**Publication Data:** ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2018 per volume:** Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-37, 1981-2017) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iia-anticancer.org)

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit www.copyright.com and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: info@copyright.com.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

D.T.P. BY IAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

## Quantitative Structure–Cytotoxicity Relationship of Azulene Amide Derivatives

KANA IMANARI<sup>1</sup>, MASASHI HASHIMOTO<sup>1</sup>, HIDETSUGU WAKABAYASHI<sup>1</sup>,  
NORIYUKI OKUDAIRA<sup>2</sup>, KENJIRO BANDOW<sup>3</sup>, JUNKO NAGAI<sup>4</sup>, MINEKO TOMOMURA<sup>3</sup>,  
AKITO TOMOMURA<sup>3</sup>, YOSHIHIRO UESAWA<sup>4</sup> and HIROSHI SAKAGAMI<sup>5</sup>

<sup>1</sup>Faculty of Science, Josai University, Sakado, Japan;

Division of <sup>2</sup>Pharmacology and <sup>3</sup>Biochemistry, and <sup>5</sup>Meikai University Research Institute of Odontology (M-RIO),  
Meikai University School of Dentistry, Sakado, Japan;

<sup>4</sup>Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan

**Abstract.** *Background/Aim:* Very few studies of anticancer activity of azulene amides led us to investigate the cytotoxicity of 21 *N*-alkylazulene-1-carboxamides introduced either with 3-methyl [1-7], 7-isopropyl-3-methyl [8-14] or 2-methoxy group [15-21]. *Materials and Methods:* Tumor-specificity (TS) was calculated by the ratio of mean 50% cytotoxic concentration (CC<sub>50</sub>) against three normal human oral mesenchymal cells to that against four human oral squamous cell carcinoma (OSCC) cell lines. Potency-selectivity expression (PSE) was calculated by dividing TS value by CC<sub>50</sub> value against OSCC cell lines. Apoptosis-inducing activity was evaluated by caspase-3 activation and appearance of subG<sub>1</sub> cell population. *Results:* [8-14] showed higher TS and PSE values, than [1-7] and [15-21]. The most active compound [8-14] induced apoptosis in C9-22 OSCC cells at 4-times higher CC<sub>50</sub>. Quantitative structure-activity relationship analysis of [1-14] demonstrated that their tumor-specificity was correlated with chemical descriptors that explain the molecular shape and hydrophobicity. *Conclusion:* 7-Isopropyl-3-methyl-*N*-propylazulene-1-carboxamide [8] can be a potential candidate of lead compound for manufacturing new anticancer drug.

Azulene, an isomer of naphthalene, is well known for its beneficial antioxidant effects. Azulene gargle has been used to reduce the incidence of undesirable general anesthesia-

induced postoperative sore (1). Sodium azulene sulfonate, a water-soluble derivative of azulene, inhibited the capsaicin-induced pharyngitis in rats, possibly by its antioxidative effect (2). Administration of 6-isopropyl-3-[4-(4-chlorophenylsulfonylamino)butyl]azulene-1-sulfonic acid sodium salt (KT2-962), a thromboxane A receptor antagonist, significantly reduced the myocardial ischemia/reperfusion injury in a dog, possibly by its direct hydroxyl radical scavenging activity (3). Azulenyl retinobenzoic acid derivatives effectively suppressed the carcinogen-induced neoplastic transformation of mouse fibroblast C3H/10T1/2 cells (4). Guaiazulene, a lipophilic azulene derivative which is abundant in nature, protected rats from paracetamol-induced hepatocytotoxicity by its antioxidant activity (inhibition of lipid peroxidation and radical scavenging action) (5). Guaiazulene also inhibited CYP1A2 that participates in the formation of toxic metabolite *N*-acetyl-*p*-benzoquinone imine (NAPQI) and the metabolic activation of several toxic and carcinogenic compounds (6). On the other hand, there is a limited number of studies that have investigated the cytotoxicity of guaiazulene against human malignant (7-9) and non-malignant cells (9, 10).

We recently reported that among ten azulene-related compounds, *N*-propylguaiazulenecarboxamide showed the highest tumor-specificity against human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) vs. three normal human oral mesenchymal cells (gingival fibroblast, HGF; periodontal ligament fibroblast, HPLF; pulp cell, HPC) (10). Furthermore, quantitative structure-activity relationship (QSAR) analysis demonstrated the tight correlation between their tumor-specificity and hydrophobicity and molecular shape (11). PubMed search revealed only one study that has investigated the anticancer activity of azulene amides (10).

In order to obtain more tumor-selective guaiazulene derivatives, we have synthesized a total of 21 *N*-alkylazulene-

Correspondence to: Hidetsugu Wakabayashi, Faculty of Science, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan. Tel: +81 492717959, Fax: +81 492717985, e-mail: hwaka@josai.ac.jp/sakagami@dent.meikai.ac.jp

Key Words: QSAR, Azulene amides, oral squamous cell carcinoma, apoptosis tumor specificity, chemical descriptor, hydrophobicity, molecular shape.




Figure 1. Structure of three groups of azulene amide derivatives used in this study.

1-carboxamide where 3-methyl, 7-isopropyl-3-methyl or 2-methoxy groups were introduced (Figure 1) and investigated their anticancer activity using four human oral squamous cell carcinoma (OSCC) cell lines and three normal human oral mesenchymal cells. We also investigated the effect of these compounds on apoptosis induction, since many anticancer drugs have been reported to induce apoptosis in clinical cancer tissues (12).

## Materials and Methods

**Materials.** The following chemicals were obtained from the indicated companies: Dulbecco's modified Eagle's medium (DMEM) from GIBCO BRL (Grand Island, NY, USA); fetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), doxorubicin-HCl (DXR) from Sigma-Aldrich Inc., (St. Louis, MO, USA); dimethyl sulfoxide (DMSO), actinomycin D (Act. D) from Wako Pure Chem. Ind., (Osaka, Japan); culture plastic dishes and 96-well plates from Techno Plastic Products AG, (Trasadingen, Switzerland). Protease and phosphatase inhibitors were purchased from Roche Diagnostics (Tokyo, Japan).

**Synthesis of alkylaminogroups.** 3-methyl-*N*-propylazulene-1-carboxamide [1], 3-methyl-*N*-butylazulene-1-carboxamide [2], 3-methyl-*N*-pentylazulene-1-carboxamide [3], 3-methyl-*N*-(2-hydroxyethyl)azulene-1-carboxamide [4], 3-methyl-*N*-(3-hydroxypropyl)azulene-1-carboxamide [5], 3-methyl-*N*-(2-methoxyethyl)azulene-1-carboxamide [6], 3-methyl-*N*-(3-methoxypropyl)azulene-1-carboxamide [7], 7-isopropyl-3-methyl-*N*-propylazulene-1-carboxamide [8], 7-isopropyl-3-methyl-*N*-butylazulene-1-carboxamide [9], 7-isopropyl-3-methyl-*N*-pentylazulene-1-carboxamide [10], 7-isopropyl-3-methyl-*N*-(2-hydroxyethyl)azulene-1-carboxamide [11], 7-isopropyl-3-methyl-*N*-(3-hydroxypropyl)azulene-1-carboxamide [12], 7-isopropyl-3-

methyl-*N*-(2-methoxyethyl)azulene-1-carboxamide [13], 7-isopropyl-3-methyl-*N*-(3-methoxypropyl)azulene-1-carboxamide [14], 2-methoxy-*N*-propylazulene-1-carboxamide [15], 2-methoxy-*N*-butylazulene-1-carboxamide [16], 2-methoxy-*N*-pentylazulene-1-carboxamide [17], 2-methoxy-*N*-(2-hydroxyethyl)azulene-1-carboxamide [18], 2-methoxy-*N*-(3-hydroxypropyl)azulene-1-carboxamide [19], 2-methoxy-*N*-(2-methoxyethyl)azulene-1-carboxamide [20], 2-methoxy-*N*-(3-methoxypropyl)azulene-1-carboxamide [21] (structures shown in Figure 1) were synthesized, according to previous reports (13-17). All compounds were dissolved in DMSO at 40 mM and stored at -20°C before use.

**Cell culture.** Human normal oral cells (HGF, HPLF, HPC) cells (18) at 12~20 population doubling level (PDL) and OSCC cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) (Riken Cell Bank, Tsukuba, Japan) were cultured at 37°C in DMEM supplemented with 10% heat-inactivated FBS and antibiotics as described previously (11).

**Assay for cytotoxic activity.** Cells were inoculated at 2×10<sup>3</sup> cells/0.1 ml in a 96-microwell plate. After 48 h, the medium was replaced with 0.1 ml of fresh medium containing different concentrations of test compounds. Control cells were treated with the same amounts of DMSO present in each diluent solution. Cells were incubated for 48 h and the relative viable cell number was then determined by the MTT method, as described previously (11). The CC<sub>50</sub> was determined from the dose-response curve of triplicate samples.

**Calculation of tumor-specificity index (TS).** TS was calculated as the ratio of mean CC<sub>50</sub> (HGF+HPLF+HPC) to mean CC<sub>50</sub> (Ca9-22+HSC-2+HSC-3+HSC-4), using seven cell lines [(D/B) in Table I] (19), and as the ratio of CC<sub>50</sub> (HGF) to CC<sub>50</sub> (Ca9-22) [(C/A) in Table I], using two cell lines derived from the gingival tissue (20). Normal keratinocytes, which are highly sensitive to many anticancer drugs (21), were not used in this study.

Table I. Cytotoxicity of 21 azulene amide derivatives and doxorubicin against human oral squamous cell carcinoma cell lines and human oral normal cells.

	CC <sub>50</sub> (μM)												
	Human oral squamous cell carcinoma cell lines					Human normal oral cells				TS		PSE	
	(A) Ca9-22	HSC-2	HSC-3	HSC-4	(B) mean	(C) HGF	HPLF	HPC	(D) mean	(D/B)	(C/A)	(D/B <sup>2</sup> )×100	(C/A <sup>2</sup> )×100
Group A													
1	279	318	364	353	329	391	394	289	358	1.1	1.4	0.3	0.5
2	139	169	148	111	142	265	285	162	237	1.7	1.9	1.2	1.4
3	76	61	66	50	63	270	299	165	245	3.9	3.6	6.1	4.7
4	388	324	400	392	376	398	396	389	395	1.0	1.0	0.3	0.3
5	382	397	398	385	391	381	400	214	332	0.8	1.0	0.2	0.3
6	377	370	362	344	363	363	400	170	311	0.9	1.0	0.2	0.3
7	284	379	288	235	296	351	391	204	315	1.1	1.2	0.4	0.4
(mean)	275	288	289	267	280	346	366	227	313	1.5	1.6	1.2	1.1
Group B													
8	35	48	47	38	42	355	400	138	298	7.1	10.1	16.9	28.5
9	36	158	38	160	98	400	400	299	366	3.7	11.1	3.8	30.8
10	43	295	33	307	170	400	400	400	400	2.4	9.3	1.4	21.7
11	145	154	114	105	129	228	245	212	228	1.8	1.6	1.4	1.1
12	137	163	112	94	127	252	283	184	240	1.9	1.8	1.5	1.3
13	85	136	113	116	112	236	248	133	206	1.8	2.8	1.6	3.3
14	54	96	67	74	73	146	143	115	135	1.9	2.7	2.5	5.0
(mean)	76	150	75	128	107	288	303	212	268	2.9	5.6	4.2	13.1
DXR	10.10	1.40	3.29	0.08	3.72	344	349	209	301	80.9	34.1	2175.8	337.8
Group C													
15	176	144	109	82	128	285	285	319	296	2.3	1.6	1.8	0.9
16	124	114	77	69	96	258	196	246	233	2.4	2.1	2.5	1.7
17	53	75	81	61	67	155	183	137	158	2.3	2.9	3.5	5.6
18	400	400	376	387	391	400	400	400	400	1.0	1.0	0.3	0.3
19	376	400	380	393	387	400	400	400	400	1.0	1.1	0.3	0.3
20	323	400	358	365	361	400	339	400	380	1.1	1.2	0.3	0.4
21	235	387	283	274	295	354	349	366	356	1.2	1.5	0.4	0.6
(mean)	241	274	238	233	246	322	307	324	318	1.6	1.6	1.3	1.4
DXR	1.92	1.68	0.01	0.01	0.90	216.6	150.2	332.7	233.2	258.2	113.1	28586.9	5905.2

CC<sub>50</sub> value was determined by dose-response experiments performed in triplicate. Ca9-22, HSC-2, HSC-3 and HSC-4: Oral squamous cell carcinoma cell lines; HGF: human gingival fibroblasts; HPLF: periodontal ligament fibroblasts; HPC: pulp cells; CC<sub>50</sub>: 50% cytotoxic concentration, DXR: doxorubicin; TS: tumor-selectivity index; PSE: potency-selectivity expression.

*Calculation of potency-selectivity expression (PSE).* PSE was calculated by dividing TS value by CC<sub>50</sub> against tumor cells (19) [(D/B<sup>2</sup>) × 100 and (C/A<sup>2</sup>) × 100] (Table I).

*Western blot analysis.* The cells were washed, lysed and their protein extracts subjected to western blot (WB) analysis, as described previously (11). The blots were probed with the primary antibody [antibodies against cleaved caspase-3 (Cell Signaling Technology Inc., Beverly, MD, USA), poly ADP-ribose polymerase (PARP) (Cell Signaling Technology Inc.) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Trevigen, Gaithersburg, MD, USA), followed by incubation with a horseradish peroxidase-conjugated secondary antibody [ $\alpha$ -rabbit IgG (DAKO, Tokyo Japan)]. The immune complexes were visualized using Pierce Western Blotting Substrate Plus (Thermo Fisher Scientific). WB results were documented and quantified using ImageQuant LAS 500 (GE Healthcare, Tokyo, Japan) (22).

*Cell cycle analysis.* Cells (approximately 10<sup>6</sup> cells) were harvested, fixed with paraformaldehyde (Wako) in PBS(-), treated with ribonuclease (RNase) A (Sigma-Aldrich Inc.), stained propidium iodide (PI) (Wako) in the presence of 0.01% NonidetP-40 (Nakalai Tesque Inc., Kyoto, Japan), filtered through Falcon® cell strainers (Corning, NY, USA) and then were subjected to cell sorting (SH800 Series, SONY Imaging Products and Solutions Inc., Atsugi, Kanagawa, Japan), as described previously (19). Cell cycle analysis was performed with Cell Sorter Software version 2.1.2. (SONY Imaging Products and Solution Inc.) (19).

*Calculation of chemical descriptors.* pCC<sub>50</sub> (i.e., the -log CC<sub>50</sub>) was used for the comparison of the cytotoxicity between the compounds, since the CC<sub>50</sub> values had a distribution pattern close to a logarithmic normal distribution. The mean pCC<sub>50</sub> values for normal cells and tumor cell lines were defined as N and T, respectively (23). The 3D-structure of each chemical structure was




Figure 2. Cytotoxicity of 3-methyl-*N*-pentylazulene-1-carboxamide [3], 7-isopropyl-3-methyl-*N*-propylazulene-1-carboxamide [8], 7-isopropyl-3-methyl-*N*-butylazulene-1-carboxamide [9] and 2-methoxy-*N*-pentylazulene-1-carboxamide [17] against human malignant and non-malignant cells. Human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) and human oral normal cells (HGF, HPLF, HPC) were treated for 48 h with the indicated concentrations of [3], [8], [9], or [17] and viable cell number was determined by the MTT method. Each value represents mean $\pm$ S.D. of triplicate assays.

drawn by Marvin Sketch ver 16 (ChemAxon, Budapest, Hungary, <http://www.chemaxon.com>), and optimized by CORINA Classic (Molecular Networks GmbH, Nürnberg, Germany) with partial charge calculations (amber-10: EHT) in Molecular Operating Environment (MOE) version 2018.0101 (Chemical Computing Group Inc., Quebec, Canada) and Dragon (Dragon 7 version 7.0.2, Kode srl., Pisa, Italy).

**Statistical analysis.** Each experimental value was expressed as the mean $\pm$ standard deviation (SD) of triplicate or quadruplicate measurements. The correlation between chemical descriptors and cytotoxicity or tumor specificity was investigated using simple regression analyses by JMP Pro version 14.0.0 (SAS Institute Inc., Cary, NC, USA). The significance level was set at  $p < 0.05$ .

## Results

**Cytotoxicity.** Twenty one azulene amides used in this study were classified into three groups, 3-methyl-*N*-alkylazulene-1-carboxamides [1-7] (Group A), 7-Isopropyl-3-methyl-*N*-alkylazulene-1-carboxamides [8-14] (Group B) and 2-methoxy-*N*-alkylazulene-1-carboxamides [15-21] (Group C) (Figure 1). We compared their cytotoxic activity against four human oral squamous cell carcinoma (OSCC) cell lines (Ca9-22, HSC-2, HSC-3, HSC-4) and three normal oral cells (HGF, HPLF, HPC), by comparing the 50% cytotoxic

concentration (CC<sub>50</sub>) determined from the dose-response curve (example shown in Figure 2) (Table I).

Generally, group B compounds showed higher cytotoxicity against OSCC cell lines (mean CC<sub>50</sub>=107  $\mu$ M) than group C (246  $\mu$ M) and group A compounds (280  $\mu$ M). Among 21 compounds, [8] showed the highest cytotoxicity (CC<sub>50</sub>=42  $\mu$ M), followed by [3] (63  $\mu$ M) and [17] (67  $\mu$ M). From the dose-response curve, [3, 8, 17] and [9] showed cytotoxic and cytostatic growth inhibition against four OSCC cell lines, respectively (Figure 2). On the other hand, group A, B and C compounds showed comparable cytotoxicity against normal oral cells (mean CC<sub>50</sub>=313, 301 and 318  $\mu$ M, respectively).

**Tumor-specificity (TS).** TS was determined by dividing the mean CC<sub>50</sub> value towards the three normal cells by the mean CC<sub>50</sub> value towards the four OSCC cell lines (D/B, Table I) or by dividing the CC<sub>50</sub> value against HGF cells by the CC<sub>50</sub> value against Ca9-22 cells, two cells derived from the gingival tissue (C/A, Table I). Among Group A, [3] showed the highest tumor-specificity (TS=3.9 in D/B; 3.6 in C/A). Among Group B, [8] showed the highest tumor-specificity (TS= 7.1 in D/B; 10.1 in C/A), followed by [9] (TS=3.7, in D/B; 11.1 in C/A). Among Group C, [17] showed the highest tumor-specificity (TS=2.3 in D/B, 2.9 in C/A) (Table I).




Figure 3. Assessment of caspase-3 activation by [3], [8], or [17]. (A) Comparison between three compounds. (B) Dose-response and (C) time course of apoptosis induction by [8]. Ca9-22 cells were incubated for 24 h with the indicated concentrations of [3], [8], or [17] or 1  $\mu$ M actinomycin D (Act D) as positive control and subjected to western blot analysis.

*PSE value.* Next, the potency-selectivity expression (PSE) value that reflects both the cytotoxicity against OSCC and tumor-specificity was determined. [8] showed much higher PSE value [16.9 in  $(D/B^2) \times 100$ ; 28.5 in  $(C/A^2) \times 100$ ], followed by [3] (PSE=6.1; 4.7), [9] (PSE=3.8; 30.8) and [17] (PSE=3.5; 5.6).

*Apoptosis induction.* Western blot analysis (Figure 3A) demonstrated that among [3], [8], and [17] compounds, [8] induced the cleavage of PARP, one of the substrates of caspase-3, most potently, followed by [17] and [3], while [17] induced cleavage of caspase-3 (producing active form)

most potently, followed by [8] and [3]. Dose-response study (Figure 3B) showed that cleavage of PARP by [8] was detected above 80  $\mu$ M, while activation of caspase-3 was detected above 160  $\mu$ M, suggesting the induction of apoptosis (24). Time course study (Figure 3C) shows that cleavage of PARP was observed at early stage (1, 2 and 4 h after treatment with 80  $\mu$ M [8]), and declined thereafter (at 24 h).

Light microscopical observation (upper column, Figure 4) revealed that cells were damaged and began to detach by treatment with higher concentrations (160 or 200  $\mu$ M) of all three compounds [3, 8, 17]. Both [17] and actinomycin D




Figure 4. Production of subG<sub>1</sub> population by [3], [8], or [17]. Ca9-22 cells were incubated for 24 or 48 h with the indicated concentrations of [3], [8], [17] or 1 μM actinomycin D (Act D) as a positive control and subjected to cell sorter analysis.






Figure 5. Determination of coefficient between chemical descriptors and cytotoxicity of 14 Group A and B compounds against tumor cells (defined as T). The mean ( $pCC_{50}$  i.e., the  $-\log CC_{50}$ ) values for tumor cell lines were defined as T.

(positive control) produced apoptotic cells (upper column, Figure 4). Cell-cycle analysis demonstrated that [17] increased the subG1 cell population to an extent similar with that of actinomycin D, while [8] was slightly less potent in apoptosis induction (lower panel, Figure 4).

**Computational analysis.** Since 3-methyl-*N*-alkylazulene-1-carboxamides [1-7] (Group A), 7-Isopropyl-3-methyl-*N*-alkylazulene-1-carboxamides [8-14] (Group B) showed a higher tumor-specificity than 2-methoxy-*N*-alkylazulene-1-carboxamides [15-21] (Group C), QSAR analysis was




Figure 6. Determination of coefficient between chemical descriptors and cytotoxicity of 14 Group A and B compounds against normal cells (defined as N). The mean ( $pCC_{50}$  i.e., the  $-\log CC_{50}$ ) values for normal cells were defined as N.

performed with Group A and B compounds [1-14]. The number of descriptors calculated from MOE and dragon was 344 and 5,255, respectively. As a result of excluding duplicate descriptors, the number of descriptors reduced to 301 and 2,765, respectively. Among a total of 3,066 descriptors, the

top six descriptors that showed the highest correlation coefficient ( $r^2$ ) to T, N and T-N are shown in Table II.

Cytotoxicity against human OSCC cell lines was correlated with descriptors SpMin1\_Bh(m) (topological shape) ( $r^2=0.827$ ,  $p<0.0001$ ), BCUT\_SLOGP\_3 (topological




Figure 7. Determination of coefficient between chemical descriptors and tumor specificity of 14 Group A and B compounds (defined as T-N).

shape) ( $r^2=0.796$ ,  $p<0.0001$ ), MATS8m (topological shape and size) ( $r^2=0.741$ ,  $p=0.0001$ ), H% (percentage of H atoms) ( $r^2=0.734$ ,  $p=0.0001$ ), Eig04\_EA(ri) (topological shape and energy) ( $r^2=0.726$ ,  $p=0.0001$ ), AMW (average molecular weight) ( $r^2=0.725$ ,  $p=0.0001$ ) (Figure 5).

Cytotoxicity against human normal oral mesenchymal cells was correlated with descriptors Depressant-50 (Drug-like indices) ( $p=0.0025$ ), Neoplastic-50 (Drug-like indices) ( $p=0.0025$ ), BCUT\_SLOGP\_2 (topological shape) ( $r^2=0.540$ ,  $p=0.0027$ ), Eig05\_AEA(dm) (topological shape

Table II. Top six chemical descriptors that correlate with cytotoxicity to tumor cells, normal cells and tumor-specificity (having the highest  $r^2$  values).

	Descriptor	Source	Meaning	Category	Explanation
T	SpMin1_Bh(m)	Dragon	Topological shape	Burden eigenvalues	Smallest eigenvalue n. 1 of Burden matrix weighted by mass
	BCUT_SLOGP_3	MOE	Topological shape	Adjacency and distance matrix descriptors	The BCUT descriptors using atomic contribution to logP (using the Wildman and Crippen SlogP method) instead of partial charge.
	MATS8m	Dragon	Topological shape and size	2D autocorrelations	Moran autocorrelation of lag 8 weighted by mass
	H%	Dragon	Percentage of H atoms	Constitutional indices	Percentage of H atoms
N	Eig04_EA(ri)	Dragon	Topological shape and energy	Edge adjacency indices	Eigenvalue n. 4 from edge adjacency mat. weighted by resonance integral
	AMW	Dragon	Average molecular weight	Constitutional indices	Average molecular weight
	Depressant-50	Dragon	Drug-like indices	Drug-like indices	Ghose-Viswanadhan-Wendoloski antidepressant-like index at 50%
	Neoplastic-50	Dragon	Drug-like indices	Drug-like indices	Ghose-Viswanadhan-Wendoloski antineoplastic-like index at 50%
T-N	BCUT_SLOGP_2	MOE	Topological shape	Adjacency and distance matrix descriptors	The BCUT descriptors using atomic contribution to logP (using the Wildman and Crippen SlogP method) instead of partial charge.
	Eig05_AEA(dm)	Dragon	Topological shape and dipole moment	Edge adjacency indices	Eigenvalue n. 5 from augmented edge adjacency mat. weighted by dipole moment
	IC2	Dragon	Topological shape	Information indices	Information Content index (neighborhood symmetry of 2-order)
	F10[C-O]	Dragon	Topological shape	2D atom pairs	Frequency of C - O at topological distance 10
T-N	vsurf_D6	MOE	3D shape and size	Surface area, volume and shape descriptors	Hydrophobic volume (8 descriptors)
	P_VSA_ppp_L	Dragon	Topological shape and lipophilicity	P_VSA-like descriptor	P_VSA-like on potential pharmacophore points, L - lipophilic
	E_str	MOE	3D shape and energy	Potential Energy descriptors	Bond stretch potential energy. In the Potential Setup panel, the term enable (Bonded) flag is ignored, but the term weight is applied.
	PEOE_VSA_NEG	MOE	Topological shape and partial charge	Partial charge descriptors	Total negative van der Waals surface area. This is the sum of the $v_i$ such that $q_i$ is negative. The $v_i$ are calculated using a connection table approximation.
	Q_VSA_NEG	MOE	Topological shape and partial charge	Partial charge descriptors	Total negative van der Waals surface area. This is the sum of the $v_i$ such that $q_i$ is negative. The $v_i$ are calculated using a connection table approximation.
	Mor27u	Dragon	3D shape and size	3D-MorSE descriptors	Signal 27/unweighted

and dipole moment) ( $r^2=0.514$ ,  $p=0.0039$ ), IC2 (topological shape) ( $r^2=0.424$ ,  $p=0.0117$ ), F10[C-O] (topological shape) ( $r^2=0.403$ ,  $p=0.0147$ ) (Figure 6).

Tumor specificity was correlated with descriptors vsurf\_D6 (3D shape and size) ( $r^2=0.815$ ,  $p<0.0001$ ), P\_VSA\_ppp\_L (topological shape and lipophilicity) ( $r^2=0.813$ ,  $p<0.0001$ ), E\_str (3D shape and energy) ( $r^2=0.792$ ,  $p<0.0001$ ), PEOE\_VSA\_NEG (topological shape and partial charge) ( $r^2=0.790$ ,  $p<0.0001$ ), Q\_VSA\_NEG (topological shape and partial charge) ( $r^2=0.790$ ,  $p<0.0001$ ), Mor27u (3D shape and size) ( $r^2=0.789$ ,  $p<0.0001$ ) (Figure 7).

## Discussion

The present study demonstrated that 7-isopropyl-3-methyl-*N*-alkylazulene-1-carboxamides [8-14] (Group B) showed slightly higher OSCC-specific cytotoxicity than 3-methyl-*N*-alkylazulene-1-carboxamides [1-7] (Group A) and 2-methoxy-*N*-alkylazulene-1-carboxamides [15-21] (Group C). Among them, 7-isopropyl-3-methyl-*N*-propylazulene-1-carboxamide [8] showed the highest tumor-specificity towards OSCC over normal oral cells, based on TS and PSE values. [8] induced apoptosis markers such as caspase-3

activation (24) and production of subG1 population (25) only at 160  $\mu\text{M}$  (Figure 3), four times the  $\text{CC}_{50}$  (42  $\mu\text{M}$ ) (Table I). On the other hand, [17], that showed lower tumor-specificity than [8] ( $\text{TS}=2.3$  vs. 7.1 (D/B), 2.9 vs. 10.1 (C/A);  $\text{PSE}=3.5$  vs. 16.9 in  $(\text{D/B}^2)\times 100$ , 5.6 vs. 28.5 in  $(\text{C/A}^2)\times 100$ ) (Table I), activated caspase-3 and produced a higher subG1 population (Figure 4). These data suggest that induction of tumor-specific cytotoxicity (anti-tumor activity) by [8] may not be mediated *via* apoptosis induction. There are many types of cell death, such as intrinsic and extrinsic apoptosis, oncosis, necroptosis, parthanatos, ferroptosis, sarmoptosis, autophagic cell death, autosis, autolysis, paraptosis, pyroptosis, phagoptosis, and mitochondrial permeability transition (26). Further study is required to investigate the possibility of the involvement of necrotic cell death, such as pyroptosis and necroptosis, in which the activation of caspase-1, IL-1 $\beta$  and IL-18IL-pathways is involved (27).

QSAR analysis with 14 Group A and B compounds demonstrated that their tumor-specificity was correlated with molecular shape (described by *vsurf\_D6*, *P\_VSA\_ppp\_L*, *E\_str*, *PEOE\_VSA\_NEG*, *Q\_VSA\_NEG*, *Mor27u*) and lipophilicity (described by *P\_VSA\_ppp\_L*) (Table II). We also reported previously that tumor-specificity of ten *N*-alkylguaiazulenecarboxamides was correlated with molecular shape (described by *vsurf\_ID1*, *vsurf\_ID5*, *vsurf\_ID4*, *vsurf\_CW4*, *vsurf\_ID3*, *vsurf\_CW3*) and hydrophobicity (described by *vsurf\_ID1*, *vsurf\_ID5*, *vsurf\_ID4*, *vsurf\_ID3*) (11). These data suggest that the antitumor-potential of guaiazulenes can be estimated by their molecular shape and hydrophobicity. By closer inspection, [9] (100~400  $\mu\text{M}$ ) and [17] (13~100  $\mu\text{M}$ ) were found to stimulate the growth of normal oral cells. The biological significance of this hormetic growth stimulation (28) remains to be investigated.

[8] and [9] have similar chemical structure to guaiazulene (1,4-dimethyl-7-isopropylazulene), all of them having isopropyl group in seven-membered ring and methyl group at the different positions. As far as we know only two studies have been published on the anticancer activity against OSCC (8, 29). More tumor-specific derivatives of [8] as a lead compound are being synthesized to examine their anti-cancer effects.

## Conflicts of Interest

The Authors confirm that there are no known conflicts of interest associated with this publication and there was no significant financial support for this work that could have influenced its outcome.

## Author's Contributions

Hiroshi Sakagami designed the study and wrote the draft of the manuscript Masashi Hashimoto and Hidetsugu Wakabayashi synthesized all compounds. Hidetsugu Wakabayashi supervised the overall study and revised the manuscript. Kana Imanari and

Noriyuki Okudaira performed the western blot analysis. Kenjiro Bandow, Mineko Tomomura and Akito Tomomura performed the cell cycle analysis. Junko Nagai and Yoshihiro Uesawa performed the QSAR analysis.

## Acknowledgements

This work was partially supported by KAKENHI from the Japan Society for the Promotion of Science (JSPS) (16K11519).

## References

- Kalil DM, Silvestro LS and Austin PN: Novel preoperative pharmacologic methods of preventing postoperative sore throat due to tracheal intubation. *AANA J* 82(3): 188-197, 2014. PMID: 25109156.
- Sakai H and Misawa M: Effect of sodium azulene sulfonate on capsaicin-induced pharyngitis in rats. *Basic Clin Pharmacol Toxicol* 96(1): 54-59, 2005. PMID: 15667596. DOI: 10.1111/j.1742-7843.2005.pto960108.x
- Ge ZD, Auchampach JA, Piper GM and Gross GJ: Comparison of cardioprotective efficacy of two thromboxane A2 receptor antagonists. *J Cardiovasc Pharmacol* 41(3): 481-488, 2003. PMID: 12605028.
- Asato AE, Peng A, Hossain MZ, Mirzadegan T and Bertram JS: Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity. *J Med Chem* 36(21): 3137-3147, 1993. PMID: 8230100.
- Kourounakis AP, Rekka EA and Kourounakis PN: Antioxidant activity of guaiazulene and protection against paracetamol hepatotoxicity in rats. *J Pharm Pharmacol* 49(9): 938-942, 1997. PMID: 9306266.
- Kourounakis AP, Rekka EA and Kourounakis PN: Effect of guaiazulene on some cytochrome P450 activities. Implication in the metabolic activation and hepatotoxicity of paracetamol. *Arch Pharm (Weinheim)* 330(1-2): 7-11, 1997. PMID: 9112807.
- Li P, Liu X, Zhu H, Tang X, Shi X, Liu Y and Li G: Unusual inner-salt guaiazulene alkaloids and bis-sesquiterpene from the South China Sea Gorgonian *Muriceides collaris*. *Sci Rep* 7(1): 7697, 2017. PMID: 28794492. DOI: 10.1038/s41598-017-08100-z
- Wakabayashi H, Hashiba K, Yokoyama K, Hashimoto K, Kikuchi H, Nishikawa H, Kurihara T, Satoh K, Shioda S, Saito S, Kusano S, Nakashima H, Motohashi N and Sakagami H: Cytotoxic activity of azulenes against human oral tumor cell lines. *Anticancer Res* 23(6C): 4747-4755, 2003. PMID: 14981922.
- Togar B, Turkez H, Hacimuftuoglu A, Tatar A and Geyikoglu F: Guaiazulene biochemical activity and cytotoxic and genotoxic effects on rat neuron and N2a neuroblastom cells. *J Intercult Ethnopharmacol* 4(1): 29-33, 2015. PMID: 26401381. DOI: 10.5455/jice.20141124062203
- Fiori J, Teti G, Gotti R, Mazzotti G and Falconi M: Cytotoxic activity of guaiazulene on gingival fibroblasts and the influence of light exposure on guaiazulene-induced cell death. *Toxicol In Vitro* 25(1): 64-72, 2011. PMID: 20854889. DOI: 10.1016/j.tiv.2010.09.008
- Wada T, Maruyama R, Irie Y, Hashimoto M, Wakabayashi H, Okudaira N, Uesawa Y, Kagaya H and Sakagami H: *In vitro* anti-tumor activity of azulene amide derivatives. *In Vivo* 32(3): 479-486, 2018. PMID: 29695549.

- 12 Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. *Blood* 89(6): 1845-1853, 1997. PMID: 9058703.
- 13 Yasunami M, Miyoshi S, Kanegae N and Takase K: A versatile synthetic method of 1-alkylazulenes and azulene by the reaction of 3-methoxycarbonyl-2*H*-cyclohepta[b]furan-2-one with in site generated enamines. *Bull Chem Soc Jpn* 66: 892-899, 1993.
- 14 Mathias LJ and Overberger CG: Simple syntheses of 1,3-bis(perfluoroacyl)azulenes and 1,3-azulenedicarboxylic acid. *J Org Chem* 45: 1701-1703, 1980.
- 15 Doukas PH and Speaker TJ: Azulene analogs of pharmacologic agents I: amides. *J Pharm Sci* 60: 184-189, 1971. PMID: 5572437.
- 16 Anderson AG and Anderson RG: The reaction of azulenes with trifluoro- and trichloroacetic anhydride. *J Org Chem* 27: 3578-3581, 1962.
- 17 Nozoe T, Wakabayashi H, Shindo K, Ishikawa S, Wu CH and Yang PW: A convenient, one-pot azulene synthesis from cyclohepta[b]furan-2-ones and vinyl ether and its analogues (III) orthoesters as reagent. *Heterocycles* 32: 213-220, 1991.
- 18 Kantoh K, Ono M, Nakamura Y, Nakamura Y, Hashimoto K, Sakagami H and Wakabayashi H: Hormetic and anti-radiation effects of tropolone-related compounds. *In Vivo* 24(6): 843-851, 2010. PMID: 21164042.
- 19 Shi H, Nagai J, Sakatsume T, Bandow K, Okudaira N, Sakagami H, Tomomura M, Tomomura A, Uesawa Y, Takao K and Sugita Y: Quantitative structure-cytotoxicity relationship of 2-(*N*-cyclicamino) chromone derivatives. *Anticancer Res* 38(7): 3897-3906, 2018. PMID: 29970510. DOI: 10.21873/anticancer.12674
- 20 Horikoshi M, Kimura Y, Nagura H, Ono T and Ito H: A new human cell line derived from human carcinoma of the gingiva. I. Its establishment and morphological studies. *Jpn J Oral Maxillofac Surg* 20: 100-106, 1974.
- 21 Sakagami H, Okudaira N, Masuda Y, Amano O, Yokose S, Kanda Y, Suguro M, Natori T, Oizumi H and Oizumi T: Induction of apoptosis in human oral keratinocyte by doxorubicin. *Anticancer Res* 37(3): 1023-1029, 2017. PMID: 28314260. DOI: 10.21873/anticancer.11412
- 22 Tomikoshi Y, Nomura M, Okudaira N, Sakagami H and Wakabayashi H: Enhancement of cytotoxicity of three apoptosis-inducing agents against human oral squamous cell carcinoma cell line by benzoxazinotropone. *In Vivo* 30(5): 645-650, 2016. PMID: 27566085.
- 23 Nagai J, Shi H, Kubota Y, Bandow K, Okudaira N, Uesawa Y, Sakagami H, Tomomura M, Tomomura A, Takao K and Sugita Y: Quantitative structure-cytotoxicity relationship of pyrano[4,3-*b*]chromones. *Anticancer Res* 38: 4449-4457, 2018. PMID: 30061209. DOI: 10.21873/anticancer.12747
- 24 Bressenot A, Marchal S, Bezdetnaya L, Garrier J, Guillemain F and Plénat F: Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. *J Histochem Cytochem* 57(4): 289-300, 2009. PMID: 19029405. DOI: 10.1369/jhc.2008.952044
- 25 Kim IH, Kwon MJ and Nam TJ: Differences in cell death and cell cycle following fucoidan treatment in high-density HT-29 colon cancer cells. *Mol Med Rep* 15(6): 4116-4122, 2017. PMID: 28487956. DOI: 10.3892/mmr.2017.6520
- 26 Fricker M, Tolkovsky AM, Borutaite V, Coleman M and Brown GC: Neuronal Cell Death. *Physiol Rev* 98(2): 813-880, 2018. PMID: 29488822. DOI: 10.1152/physrev.00011.2017
- 27 Frank D and Vince JE: Pyroptosis *versus* necroptosis: similarities, differences, and crosstalk. *Cell Death Differ* 26(1): 99-114, 2019. PMID: 30341423. DOI: 10.1038/s41418-018-0212-6
- 28 Calabrese EJ: Biphasic dose responses in biology, toxicology and medicine: accounting for their generalizability and quantitative features. *Environ Pollut* 182: 452-460, 2013. PMID: 23992683. DOI: 10.1016/j.envpol.2013.07.046
- 29 Uehara M, Minemura H, Ohno T, Hashimoto M, Wakabayashi H, Okudaira N and Sakagami H: *In vitro* antitumor activity of alkylaminoguaiazulenes. *In Vivo* 32(3): 541-547, 2018. PMID: 29695558.

Received March 18, 2019

Revised April 12, 2019

Accepted April 15, 2019

## Instructions for Authors 2019

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. References should include PMID and DOI (if applicable).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email ([iar@iar-anticancer.org](mailto:iar@iar-anticancer.org)) within two days.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.



5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2019** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.